What question did this study set out to answer?

The central aim is to evaluate the clinical efficacy of pharmacogenomic-guided treatment in schizophrenia patients.

April 25, 2026British Journal of Clinical Pharmacology0 citations

Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients

Key Points

The central aim is to evaluate the clinical efficacy of pharmacogenomic-guided treatment in schizophrenia patients.
Investigated hospitalized patients diagnosed with schizophrenia.
Applied combinatorial pharmacogenomics (CPGx) to guide treatment decisions.
Significant improvement in treatment outcomes with CPGx guidance in schizophrenia patients.

Abstract

Our findings demonstrate that CPGx significantly improves treatment outcomes in hospitalized patients with schizophrenia, supporting that CPGx can guide treatment.

问 AI

Bookmark

View Full Paper